UTI Asset Management Company Ltd Valuation Shifts to Very Attractive Amid Market Volatility

Valuation Metrics Reflect Enhanced Appeal

UTI AMC’s current price-to-earnings (P/E) ratio stands at 19.79, a figure that positions the stock favourably within the capital markets sector. This P/E is significantly lower than many of its peers, several of which are trading at very expensive multiples. For instance, Go Digit General and Star Health Insurance command P/E ratios exceeding 60, while Aditya AMC and Anand Rathi Wealth Management are priced at 25.53 and 69.41 respectively. This disparity underscores UTI AMC’s relative valuation advantage.

Complementing the P/E ratio, the price-to-book value (P/BV) of 2.90 further supports the stock’s attractive valuation status. While not the lowest in the sector, it remains reasonable given the company’s robust return on capital employed (ROCE) of 21.95% and return on equity (ROE) of 13.41%. These profitability metrics indicate efficient capital utilisation and shareholder value creation, justifying a premium over book value.

Enterprise Value Multiples and Dividend Yield

Examining enterprise value (EV) multiples, UTI AMC’s EV to EBIT ratio is 13.09 and EV to EBITDA is 12.44, both of which are moderate compared to peers. For example, Go Digit General’s EV to EBITDA ratio is an elevated 126.59, signalling a stretched valuation. The EV to capital employed ratio of 3.10 and EV to sales of 6.62 also reflect a balanced valuation stance, neither excessively cheap nor overpriced.

Investors may find the dividend yield of 4.84% particularly appealing in the current environment, offering a steady income stream alongside capital appreciation potential. This yield is competitive within the capital markets sector, where dividend payouts can vary widely.

Market Performance and Price Movements

Despite the improved valuation metrics, UTI AMC’s share price has experienced some volatility. The stock closed at ₹989.45 on 2 March 2026, down 3.91% from the previous close of ₹1,029.70. The day’s trading range was between ₹981.50 and ₹1,025.00, reflecting intraday uncertainty. Over the past week, the stock declined by 7.52%, underperforming the Sensex’s 1.84% drop. However, over the one-month horizon, UTI AMC rebounded with a 3.6% gain, outperforming the Sensex’s 0.7% decline.

Year-to-date, the stock has declined 12.36%, lagging the Sensex’s 4.62% fall. Over longer periods, UTI AMC has delivered strong returns, with a three-year gain of 51.99% versus the Sensex’s 37.10%, and a five-year return of 68.05% compared to the benchmark’s 65.55%. These figures highlight the company’s capacity for sustained growth despite short-term headwinds.

Peer Comparison Highlights Valuation Edge

When compared with its peers in the capital markets sector, UTI AMC’s valuation stands out as very attractive. The company’s Mojo Score is 47.0, with a Mojo Grade recently downgraded from Hold to Sell as of 30 October 2025. This downgrade reflects caution due to recent price declines and sector headwinds, despite the improved valuation parameters.

Among peers, several companies are rated as very expensive, including Go Digit General, Star Health Insurance, and Anand Rathi Wealth Management. Others like New India Assurance and Angel One hold fair valuations, while IIFL Finance is classified as expensive. UTI AMC’s very attractive valuation rating suggests it may offer better value for investors seeking exposure to the capital markets sector.

Quality and Profitability Metrics Support Valuation

UTI AMC’s ROCE of 21.95% and ROE of 13.41% indicate solid operational efficiency and shareholder returns. These figures are critical in justifying the current valuation multiples, especially the P/E and P/BV ratios. The company’s EV to EBIT and EV to EBITDA ratios also suggest that the market is not overpaying for earnings or cash flow, which is a positive sign for value-conscious investors.

Moreover, the PEG ratio stands at 0.00, which may indicate either a lack of earnings growth expectations or a data anomaly. Nonetheless, the overall valuation framework points towards a stock that is attractively priced relative to its earnings and book value, especially when contrasted with the broader sector.

Risks and Market Sentiment

Despite the attractive valuation, investors should be mindful of the recent negative price momentum and the downgrade in Mojo Grade to Sell. The stock’s underperformance relative to the Sensex in the short term signals caution. Additionally, the capital markets sector faces regulatory and macroeconomic challenges that could impact earnings visibility and investor sentiment.

Investors should weigh these risks against the valuation appeal and consider the company’s long-term growth prospects and dividend yield when making investment decisions.

Conclusion: Valuation Shift Offers Opportunity Amid Caution

UTI Asset Management Company Ltd’s transition from a fair to a very attractive valuation grade marks a significant development for investors evaluating the capital markets sector. The company’s P/E ratio of 19.79 and P/BV of 2.90, combined with strong profitability metrics and a healthy dividend yield, present a compelling case for value-oriented investors.

However, the recent downgrade in Mojo Grade to Sell and short-term price weakness highlight the need for caution. Market participants should balance the valuation appeal against sector risks and the company’s recent performance trends. Long-term investors with a focus on capital appreciation and income may find UTI AMC’s current price levels an opportune entry point, especially when viewed against the backdrop of its robust three- and five-year returns relative to the Sensex.

In summary, while UTI AMC’s valuation parameters have improved markedly, signalling enhanced price attractiveness, investors should remain vigilant and consider peer comparisons and broader market conditions before committing fresh capital.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →